当前位置: 首页 > 期刊 > 《上海医药》 > 2018年第17期
编号:13296795
卒中后认知功能障碍的药物治疗(4)
http://www.100md.com 2018年6月15日 《上海医药》 2018年第17期
     [15] Orgogozo JM, Rigaud AS, St?ffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial(MMM 300) [J]. Stroke, 2002, 33(7): 1834-1839.

    [16] Wilcock G, M?bius HJ, St?ffler A. A double-blind, placebocontrolled multicentre study of memantine in mild to moderate vascular dementia (MMM500) [J]. Int Clin Psychopharmacol, 2002, 17(6): 297-305.

    [17] Alvarez-Sabin J, Santamarina E, Maisterra O, et al. Longterm treatment with citicoline prevents cognitive decline and predicts a better quality of life after a first ischemic stroke[J/OL]. Int J Mol Sci, 2016, 17(3): 390 [2018-04-17]. doi: 10.3390/ijms17030390.

    [18] Wang BW, Lu E, Mackenzie IR, et al. Multiple pathologies are common in Alzheimer patients in clinical trials [J]. Can J Neurol Sci, 2012, 39(5): 592-599.

    [19] Ye BS, Seo SW, Kim JH, et al. Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia [J]. Neurology, 2015, 85(19): 1687-1693., 百拇医药(刘黔云 韩燕)
上一页1 2 3 4